Chibuzo Ilonze

Chibuzo Ilonze

Auto-generated profile, based on publicly available information

Chibuzo Ilonze

Division of Pediatric Hematology Oncology and Blood and Marrow Transplantation Department of Pediatrics University of Alabama at Birmingham Birmingham Alabama USA

Research Focus & Metrics

Academic Career Length

13Years (2014-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
9 October 2014 in Journal of Assisted Reproduction and Genetics
Verified
Journal Article
Closed access
PDF file
CBCeleste D. Butts
Celeste D. Butts
MBMichael Bloom
Michael Bloom
CFCheryl A. Frye
Cheryl A. Frye
AWAlicia A. Walf
Alicia A. Walf
PPPatrick J Parsons
Patrick J Parsons
VFVictor Y. Fujimoto
Victor Y. Fujimoto

11 January 2023 in Pediatric Blood & Cancer
Verified
Journal Article
Closed access
PDF file
DPDakshin Padmanabhan
Dakshin Padmanabhan
TTTiffany Tucker
Tiffany Tucker
DMDonna Murdaugh
Donna Murdaugh
CIChibuzo Ilonze
Chibuzo Ilonze
JLJeffrey Lebensburger
Jeffrey Lebensburger
STS. Justin Thomas
S. Justin Thomas

16 November 2021 in Pediatric Blood & Cancer
Verified
Journal Article
Closed access
PDF file
CIChibuzo Ilonze
Chibuzo Ilonze
MAMichael Anderson
Michael Anderson
ASAlex Stubblefield
Alex Stubblefield
JJJanna Journeycake
Janna Journeycake
ASArpan A. Sinha
Arpan A. Sinha

14 April 2025 in Pediatric Blood & Cancer
Verified
Journal Article
Open access
CIChibuzo Ilonze
Chibuzo Ilonze
ABAlexandria Broadnax
Alexandria Broadnax
HHHilary Haines
Hilary Haines
JLJeffrey Lebensburger
Jeffrey Lebensburger
FGFrederick Goldman
Frederick Goldman
Background: Hematopoietic stem cell transplantation (HSCT) is a curative treatment for sickle cell disease (SCD). However, barriers exist that prevent access to this treatment modality. Methods: An IRB‐approved mixed‐method survey of barriers to HSCT in SCD was given to parents, caregivers, and adolescents obtaining care at the Children's of Alabama/University of Alabama at Birmingham Comprehensive Pediatric Sickle Cell Clinic. Results: We performed 103 surveys; 97 surveys (94%) were completed by a parent/guardian/caregiver, and 6 (6%) were completed by the patient. The most common SCD complication reported was three or more yearly pain crises (43%). Most (57%) respondents heard about HSCT from their healthcare provider. The most important concern with HSCT identified by respondents (67%) was the possibility of end‐organ damage with the potential to worsen over time. The greatest barrier for respondents (77%) was a 5% chance of death with HSCT. Other barriers identified include the risk of reversible or permanent organ damage (73%), HSCT failure (54%), and infertility (42%). Conclusion: Respondents identified barriers to HSCT; however, they are not insurmountable. Provider education regarding the benefits and potential risks of HSCT with a clear explanation of mitigation strategies can improve acceptance of HSCT among the SCD population.

21 April 2024 in Pediatric Blood & Cancer
Verified
Journal Article
Open access
CIChibuzo Ilonze
Chibuzo Ilonze
PRParul Rai
Parul Rai
NGNajibah Galadanci
Najibah Galadanci
RZRima Zahr
Rima Zahr
VOVictoria I. Okhomina
Victoria I. Okhomina
AAAmmar Saadoon Alishlash
Ammar Saadoon Alishlash
Background: Tricuspid regurgitation velocity (TRV), measured by echocardiography, is a surrogate marker for pulmonary hypertension. Limited pediatric studies have considered the association between TRV and surrogate markers of end‐organ disease. Methods: We conducted a cross‐sectional study that evaluated the prevalence of elevated TRV ≥2.5 m/s and its associations with renal and cerebrovascular outcomes in children with sickle cell disease (SCD) 1–21 years of age in two large sickle cell cohorts, the University of Alabama at Birmingham (UAB) sickle cell cohort, and the Sickle Cell Clinical Research and Intervention Program (SCCRIP) cohort at St. Jude Children's Research Hospital. We hypothesized that patients with SCD and elevated TRV would have higher odds of having either persistent albuminuria or cerebrovascular disease. Results: We identified 166 children from the UAB cohort (mean age: 13.49 ± 4.47 years) and 325 children from the SCCRIP cohort (mean age: 13.41 ± 3.99 years) with echocardiograms. The prevalence of an elevated TRV was 21% in both UAB and SCCRIP cohorts. Elevated TRV was significantly associated with cerebrovascular disease (odds ratio [OR] 1.88, 95% confidence interval [CI]: 1.12–3.15; p = .017) and persistent albuminuria (OR 1.81, 95% CI: 1.07–3.06; p = .028) after adjusting for age, sex, treatment, and site. Conclusion: This cross‐sectional, multicenter study identifies associations between surrogate markers of pulmonary hypertension with kidney disease and cerebrovascular disease. A prospective study should be performed to evaluate the longitudinal outcomes for patients with multiple surrogate markers of end‐organ disease.

25 September 2019 in Pediatric Blood & Cancer
Verified
Journal Article
Closed access
PDF file
ASAnand Srinivasan
Anand Srinivasan
CIChibuzo C Ilonze
Chibuzo C Ilonze
STStephen R. Travis
Stephen R. Travis
DCDavid Crawford
David Crawford